Agrima Mian, MD
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Diffuse large b-cell lymphoma (DLBCL)
- Non-Hodgkin lymphoma (NHL)
- Hodgkin lymphoma (Hodgkin’s disease)
My Specialties
- Immunotherapy
- Targeted therapy
- CAR T-cell therapy
Get to Know Me
I’m a medical oncologist and hematologist who is an expert in caring for people with lymphoma. This includes Hodgkin lymphoma and non-Hodgkin lymphomas.
Lymphomas are a diverse group of cancers that develop in cells of the immune system and are the most common type of blood cancer. There are many types of lymphoma, and treatment can differ from one person to another.
I see patients at the David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center (MSK) in Manhattan and MSK Westchester.
I understand that a cancer diagnosis can be life-changing for you and your family. My approach is to combine expertise with careful listening. I take the time to understand your diagnosis, priorities, and concerns, and develop a treatment plan that is right for you. I make sure you understand not only what I recommend, but also why. I encourage questions and making decisions together so that you and your family can feel informed and supported.
I have a special focus on newer lymphoma treatments. This includes CAR T cell therapy, bispecific antibodies, immunotherapy, and targeted therapies. My research focuses on developing and studying cellular and immune-based therapies. These treatments are for aggressive lymphomas and also for when the disease has returned or has not responded to standard treatments.
Through research and clinical trials, my aim is to expand treatment options. I work to move promising therapies from scientific discovery into better care for patients.
I also have a special interest in caring for adolescents and young adults with cancer. A cancer diagnosis at a young age can affect many aspects of life beyond the cancer itself. I work with a team of different experts to address issues such as fertility, sexual and mental health, long-term effects of treatment, and survivorship. My goal is to help young people live well during and after cancer treatment.
Outside of work, I enjoy traveling, exploring hiking trails and coffee shops. I also love reading stories with my child, and spending time with family and friends.
I'm a lymphoma specialist, which is a doctor with special training in diagnosing and treating lymphoma (lim-FOH-muh). This cancer starts in the cells of the immune system.
A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.
- Assistant Attending Physician
Conditions I Treat
- Diffuse large b-cell lymphoma (DLBCL)
- Non-Hodgkin lymphoma (NHL)
- Hodgkin lymphoma (Hodgkin’s disease)
- Central nervous system (CNS) lymphoma
- Burkitt lymphoma
- Chronic lymphocytic leukemia (CLL)
- Mantle cell lymphoma (MCL)
- Follicular lymphoma
- Peripheral T-cell lymphomas
- Lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia)
My Specialties
- Immunotherapy
- Targeted therapy
- CAR T-cell therapy
- Clinical trials
- Adolescent and young adult (AYA) cancer care
Education
- MBBS, Kasturba Medical College (KMC), Manipal University, India
- MD, All India Institute of Medical Sciences (AIIMS), India
Residencies
- Internal Medicine, Cleveland Clinic
Fellowships
- Lymphoma and Cellular Therapy, Cleveland Clinic
- Hematology and Medical Oncology, Cleveland Clinic
Board Certifications
- Internal Medicine
- Medical Oncology (board eligible)
- Hematology (board eligible)
Awards and Honors
- Young Investigator Award, Women Who Conquer Cancer, American Society of Clinical Oncology (ASCO) (2026-2027)
- Research Training Award for Fellows (RTAF), American Society of Hematology (ASH) (2025-2026)
- Scholar of ASCO/AACR Methods in Clinical Cancer Research Workshop (Vail), American Society of Clinical Oncology (ASCO)/American Association of Cancer Research (AACR) (2024)
- Scholar of Clinical Research Training Course (CRTC), American Society for Transplantation and Cellular Therapy (ASTCT) (2024) Hematology Opportunities for Next Generation of Research Scientists (HONORS) Award, American Society of Hematology (2023-2024)
- F. Merlin Bumpus Junior Investigator Award for Best Clinical Research, Lerner Research Institute, Cleveland Clinic (2020)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, EPO PPO, POS, Transplant
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO, HMO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
HMO, PPO
Starting January 1, 2027, MSK will no longer be in-network for Healthfirst Medicare plans. This applies to all Healthfirst Medicare Advantage plans and dual-eligible Medicare Advantage special needs plans.
In Network Coverage Type
HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
POS, HMO
In Network Coverage Type
State Government
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO
This is a dual payer plan, which means 2 health insurance companies share this plan. MSK providers are out-of-network with UnitedHealthcare.
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO
In Network Coverage Type
State Government
This plan is in-network at our New York sites only.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO EPO
In Network Coverage Type
HMO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
PPO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
EPO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
EPO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
TBD
In Network Coverage Type
PPO, POS, EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO (City Employee Health Plans Gold and Gold Care Only)
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO/OAP
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, EPO
In Network Coverage Type
State Government
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, POS
In Network Coverage Type
PPO, POS, HMO
Learn more about the insurance plans that participate with MSK.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
Health plans can change at any time. Call the number on the back of your insurance card to see what your plan covers. Make sure it covers the MSK location where you’ll get care.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Mian A, Litvin R, Dima D, Hamilton BK, Winter A, Khouri J, Williams L, Raza S, Jagadeesh D, Gerds AT, Dean RM, Sobecks RM, Anwer F, Kalaycio ME, Brunstein CG, Sauter CS, Pasquini M, Hill BT, Caimi PF. Neighborhood Socioeconomic Disadvantage and Distance From Treatment Center do not Impact Survival Outcomes of Patients With Non-Hodgkin Lymphoma and Multiple Myeloma Treated With CAR T-Cell Therapies. Transplant Cell Ther. 2026 Jun 10:S2666-6367(26)00430-6. doi: 10.1016/j.jtct.2026.05.039. Epub ahead of print. PMID: 42269871.
Mian A, Reyes-García H. The conversations that shape cancer care: lessons learned from communicating with patients. ASCO Connection. September 11, 2026. Accessed October 9, 2026. https://connection.asco.org/do/conversations-shape-cancer-care-lessons-learned-communicating-patients
Stuver R, Mian A, Brown S, Devlin S, Caimi PF, Chinapen S, Dahi P, Dean R, Epstein-Peterson ZD, Hill B, Horwitz SM, Lahoud O, Lin R, Moskowitz AJ, Sauter C, Shah G, Winter A, Jagadeesh D, Scordo M. BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Am J Hematol. 2024 Jun;99(6):1180-1183. doi: 10.1002/ajh.27291. Epub 2024 Mar 25. PMID: 38526002; PMCID: PMC11096040.
Mian A, Wei W, Hamilton BK, Winter AM, Khouri J, Pohlman B, Gerds AT, Jagadeesh D, Anwer F, Kalaycio M, Dean RM, Sobecks R, Caimi PF, Hill BT, Majhail NS. Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel. Bone Marrow Transplant. 2023 May;58(5):590-593. doi: 10.1038/s41409-023-01934-4. Epub 2023 Feb 11. PMID: 36774431.
Mian A, Wei W, Winter AM, Khouri J, Jagadeesh D, Anwer F, Gerds AT, Dean RM, Sobecks R, Pohlman B, Hamilton BK, Majhail NS, Hill BT. Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. Leuk Lymphoma. 2021 Jun;62(6):1344-1352. doi: 10.1080/10428194.2020.1864349. Epub 2020 Dec 29. PMID: 33375873.
Visit PubMed for a full listing of Dr. Mian’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.